Perinatal EvidenceCompass
Prepopulated workbenchMED-111

Antipsychotics — second generation/newer

Xanomeline/trospium chloride

Second-generation or newer antipsychotic

Brand / product examples: Cobenfy

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Xanomeline/trospium chloride
Entity type
fixed-dose combination
Active component(s)
Xanomeline (as xanomeline tartrate) · trospium chloride
Formulation / route / interval
Oral capsule; twice daily
Attachment entry
Xanomeline/trospium
Separate monograph status
Yes — fixed combination plus both component cross-references
Identity and cross-reference
Create component cross-references for xanomeline and trospium; do not treat as a single new molecule
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

3 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

B-054Evidence gap

Human pregnancy data are insufficient for xanomeline/trospium, and dopamine-antipsychotic neonatal EPS warnings should not be mechanically extrapolated.

Public-source certainty descriptor
regulatory label; very low clinical evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy
Comparator
not estimable
Effect or numbers carried forward

No adequate human pregnancy cohort

Limitations

New product, different mechanism, no comparative pregnancy PK or child follow-up.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-063Provisional public source

A stable patient should not be switched reflexively after conception solely to use a medicine with more pregnancy data.

Public-source certainty descriptor
guideline recommendation
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
after conception
Comparator
continuing an effective regimen
Effect or numbers carried forward

No single effect estimate; relapse and fetal polypharmacy tradeoff

Limitations

Important exceptions include valproate and compelling toxicity/ineffectiveness; individual history controls the decision.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
B-064Provisional public source

If an antipsychotic was effective throughout pregnancy, routine postpartum switching solely for lactation is usually discouraged.

Public-source certainty descriptor
guideline recommendation
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
postpartum/lactation
Comparator
switching to a different agent
Effect or numbers carried forward

No single effect estimate

Limitations

Clozapine, milk-supply goals with aripiprazole, infant prematurity/illness, and long-lived/LAI exposure may change the decision.

Sources, citation controls, and verification state
PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending